In premenopausal women with idiopathic osteoporosis, lower bone formation rate is associated with higher body fat and higher IGF-1.


Journal

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 28 05 2021
accepted: 05 10 2021
pubmed: 20 10 2021
medline: 17 2 2022
entrez: 19 10 2021
Statut: ppublish

Résumé

We examined serum IGF-1 in premenopausal IOP, finding relationships that were opposite to those expected: higher IGF-1 was associated with lower bone formation and higher body fat, and lower BMD response to teriparatide. These paradoxical relationships between serum IGF-1, bone, and fat may contribute to the mechanism of idiopathic osteoporosis in premenopausal women. Premenopausal women with idiopathic osteoporosis (IOP) have marked deficits in bone microarchitecture but variable bone remodeling. We previously reported that those with low tissue-level bone formation rate (BFR) are less responsive to teriparatide and have higher serum IGF-1, a hormone anabolic for osteoblasts and other tissues. The IGF-1 data were unexpected because IGF-1 is low in other forms of low turnover osteoporosis-leading us to hypothesize that IGF-1 relationships are paradoxical in IOP. This study aimed to determine whether IOP women with low BFR have higher IGF-1 and paradoxical IGF-1 relationships in skeletal and non-skeletal tissues, and whether IGF-1 and the related measures predict teriparatide response. This research is an ancillary study to a 24 month clinical trial of teriparatide for IOP. Baseline assessments were related to trial outcomes: BMD, bone remodeling.  Premenopausal women with IOP(n = 34); bone remodeling status was defined by baseline cancellous BFR/BS on bone biopsy.  Serum IGF-1 parameters, compartmental adiposity (DXA, CT, MRI), serum hormones, and cardiovascular-risk-markers related to fat distribution. As seen in other populations, lower BFR was associated with higher body fat and poorer teriparatide response. However, in contrast to observations in other populations, low BFR, higher body fat, and poorer teriparatide response were all related to higher IGF-1: IGF-1 Z-score was inversely related to BFR at all bone surfaces (r =  - 0.39 to - 0.46; p < 0.05), directly related to central fat (p = 0.05) and leptin (p = 0.03). IGF-1 inversely related to 24 month hip BMD %change (r =  - 0.46; p = 0.01). Paradoxical IGF-1 relationships suggest that abnormal or atypical regulation of bone and fat may contribute to osteoporosis mechanisms in premenopausal IOP.

Identifiants

pubmed: 34665288
doi: 10.1007/s00198-021-06196-8
pii: 10.1007/s00198-021-06196-8
pmc: PMC9927557
mid: NIHMS1869010
doi:

Substances chimiques

Bone Density Conservation Agents 0
Teriparatide 10T9CSU89I
Insulin-Like Growth Factor I 67763-96-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

659-672

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK026687
Pays : United States
Organisme : FDA HHS
ID : R01 FD003902
Pays : United States
Organisme : NIAMS NIH HHS
ID : R03 AR064016
Pays : United States

Informations de copyright

© 2021. International Osteoporosis Foundation and National Osteoporosis Foundation.

Références

Lancet Diabetes Endocrinol. 2014 Jul;2(7):581-92
pubmed: 24731664
Osteoporos Int. 2011 Jun;22(6):1703-8
pubmed: 20827548
Clin Orthop Relat Res. 1971 Oct;80:147-54
pubmed: 5133320
J Clin Endocrinol Metab. 2010 Mar;95(3):1247-55
pubmed: 20080853
J Pathol Bacteriol. 1967 Oct;94(2):275-91
pubmed: 6066476
J Clin Endocrinol Metab. 2008 Oct;93(10):3785-93
pubmed: 18682511
J Clin Invest. 1991 Apr;87(4):1241-50
pubmed: 1707060
J Clin Endocrinol Metab. 2007 Apr;92(4):1542-8
pubmed: 17264177
J Clin Endocrinol Metab. 2013 Jun;98(6):2562-72
pubmed: 23515452
J Appl Physiol (1985). 2009 Feb;106(2):418-22
pubmed: 19095751
J Clin Endocrinol Metab. 2001 Nov;86(11):5509-15
pubmed: 11701729
J Clin Endocrinol Metab. 2009 Jun;94(6):2129-36
pubmed: 19318450
J Bone Miner Res. 2010 Apr;25(4):757-68
pubmed: 19821771
Endocr Dev. 2013;24:128-37
pubmed: 23392101
J Bone Miner Res. 2005 Jun;20(6):962-70
pubmed: 15883636
Curr Osteoporos Rep. 2014 Mar;12(1):82-9
pubmed: 24419863
Calcif Tissue Int. 2010 Dec;87(6):485-92
pubmed: 20953593
Diabetes Obes Metab. 2009 Apr;11(4):275-84
pubmed: 18671797
Obesity (Silver Spring). 2011 Jan;19(1):49-53
pubmed: 20467419
J Clin Endocrinol Metab. 1998 Feb;83(2):382-95
pubmed: 9467546
J Bone Miner Res. 2013 Jan;28(1):2-17
pubmed: 23197339
J Clin Endocrinol Metab. 2014 May;99(5):1675-86
pubmed: 24483154
J Clin Endocrinol Metab. 1997 Sep;82(9):2799-805
pubmed: 9284699
J Clin Endocrinol Metab. 2020 Oct 1;105(10):
pubmed: 32876328
Ann Med Interne (Paris). 1998 Mar;149(2):77-81
pubmed: 11490528
J Comput Assist Tomogr. 2006 Sep-Oct;30(5):777-83
pubmed: 16954927
Endocrinology. 1990 Oct;127(4):1804-10
pubmed: 2401235
Eur J Endocrinol. 2010 Aug;163(2):185-91
pubmed: 20501597
J Clin Endocrinol Metab. 1995 Jan;80(1):153-9
pubmed: 7829604
Osteoporos Int. 2002;13(4):337-41
pubmed: 12030549
J Bone Miner Res. 2017 Jun;32(6):1267-1273
pubmed: 28218468
Osteoporos Int. 2007 May;18(5):641-7
pubmed: 17139464
Bone. 2022 Jan;154:116253
pubmed: 34743040
J Clin Endocrinol Metab. 2013 Jul;98(7):2854-63
pubmed: 23666961
Diabetes Care. 2004 Jun;27(6):1487-95
pubmed: 15161807
Bone. 2011 Apr 1;48(4):748-54
pubmed: 21195217
Biogerontology. 2001;2(3):165-71
pubmed: 11708718
Osteoporos Int. 2015 Oct;26(10):2471-8
pubmed: 25986383
Eur J Endocrinol. 2009 Nov;161 Suppl 1:S97-S106
pubmed: 19684058
J Clin Endocrinol Metab. 2013 May;98(5):1971-81
pubmed: 23543660
J Clin Endocrinol Metab. 2011 Oct;96(10):3095-105
pubmed: 21832117
J Clin Pathol. 2002 Sep;55(9):693-8
pubmed: 12195001
J Clin Endocrinol Metab. 2009 Sep;94(9):3387-93
pubmed: 19531595
J Clin Endocrinol Metab. 2009 Nov;94(11):4351-60
pubmed: 19837923
Eur J Endocrinol. 2006 Jul;155(1):79-90
pubmed: 16793953
J Clin Endocrinol Metab. 2012 Aug;97(8):2782-91
pubmed: 22701013
J Bone Miner Res. 2007 Nov;22(11):1798-807
pubmed: 17645402

Auteurs

T G Goetz (TG)

Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.

N Nair (N)

Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.

S Shiau (S)

Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA.

R R Recker (RR)

Department of Medicine, Creighton University Medical Center, Omaha, NE, USA.

J M Lappe (JM)

Department of Medicine, Creighton University Medical Center, Omaha, NE, USA.

D W Dempster (DW)

Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.

H Zhou (H)

Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, USA.

B Zhao (B)

Department of Radiology, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.

X Guo (X)

Department of Radiology, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.

W Shen (W)

Department of Pediatrics, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Institute of Human Nutrition, Columbia University Irving Medical Center, New York, NY, USA.
Columbia Magnetic Resonance Research Center (CMRRC), Columbia University, New York, NY, USA.

T L Nickolas (TL)

Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.

M Kamanda-Kosseh (M)

Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.

M Bucovsky (M)

Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.

J Stubby (J)

Department of Medicine, Creighton University Medical Center, Omaha, NE, USA.

E Shane (E)

Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.

A Cohen (A)

Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA. ac1044@columbia.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH